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SUMMARY – Th e prevalence of chronic hepatitis C increases in elderly patients. Th e aims of this 
study were to identify the factors associated with hepatocellular carcinoma (HCC) and end-stage liver 
disease development and to evaluate the effi  cacy and safety of pegylated interferon (PEG-IFNα) plus 
ribavirin (RBV) therapy in elderly patients. A retrospective cohort study included all consecutive 
 patients with hepatitis C virus (HCV) infection treated with PEG-IFNα+RBV between 2003 and 
2013. Elderly patients had a higher frequency of poor prognostic factors including genotype 1 infection, 
high fi brosis, and high fi brosis index based on four factors (FIB-4) score. Th e sustained virologic 
 response (SVR) rate for genotype 1 was signifi cantly lower (35.8% vs. 57.1%), while the frequency of 
PEG-IFNα (27.2% vs. 7.8%), RBV dose reduction (19.6% vs. 9.7%) and treatment discontinuation 
(13.0% vs. 4.1%) was signifi cantly higher in elderly patients. However, age was not associated with SVR 
in multivariate analysis, and comparable SVR rates were achieved when adjusted for fi brosis score 
(Ishak ≤3: 66.7% vs. 69.8%). During the follow-up, HCC was diagnosed in 18 elderly patients (3 
SVR+, 4 SVR- and 9 untreated patients). In conclusion, selected elderly patients can achieve compa-
rable SVR rates as younger patients, but with a higher rate of side eff ects. Since complications of HCV 
infection occur more frequently in elderly patients, they should be given priority for antiviral therapy.
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Introduction
Chronic hepatitis C (CHC) continues to be a ma-
jor public health problem. Despite the limited number 
of population-based studies on the age-specifi c preva-
lence, HCV prevalence increases with age, and cur-
rently the age group with the peak prevalence in Eu-
rope is the 55-65 age group1, 2. While the mean life 
expectancy in the European Union (EU) is 19.8 years 
once a man reaches the age of 65 (according to the 
EuroStat), it is expected that HCV related liver cir-
rhosis and hepatocellular carcinoma (HCC) will dra-
matically increase in the following years, particularly 
in the elderly population3.
Aging is considered as an unfavorable factor for 
liver disease progression; adults older than 60 more of-
ten present with complications of cirrhosis and HCC 
as initial manifestations of HCV infection; older age 
at the time of initial infection is associated with more 
rapid progression to fi brosis, cirrhosis and infectious 
complications; elderly patients are at an increased risk 
of HCC, even if they achieve sustained viral response 
(SVR) in the absence of signifi cant fi brosis or cirrho-
sis4-6. Although this age group was excluded from the 
initial pegylated interferon plus ribavirin (PEG-
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IFNα+RBV) registration trials, these studies identi-
fi ed age ≥60 years to be associated with poorer treat-
ment response7,8. Th e safety and effi  cacy of HCV 
therapies have been extensively studied in patients 
between the ages of 18 and 60, but elderly patients 
remain an understudied and diffi  cult-to-treat popula-
tion. Th e ‘real-life’ studies of PEG-IFNα+RBV treat-
ment in elderly individuals are scarce. Although gener-
ally thought as a negative predictor of SVR, the pub-
lished results of therapy effi  cacy in elderly patients are 
disagreeing. While some studies showed the treatment 
to be well tolerated and there was little or no diff erence 
in SVR, other showed marked reduction in SVR rates6, 
9-12. Nevertheless, older age is still associated with a 
lower likelihood of being considered for antiviral ther-
apy13, 14.
Not long ago, direct acting antiviral agents (DAAs) 
that markedly increase SVR have been licensed, but 
the effi  cacy and toxicity of these drugs in elderly popu-
lation is still unknown. Importantly, due to the price 
concerns, it is unlikely that this treatment will soon 
become widely available in low-income countries. 
Th us, the ways of stratifying patients that might ben-
efi t from PEG-IFNα+RBV backbone therapy are of 
high importance.
Th erefore, we performed a retrospective cohort 
study to examine disease progression in elderly pa-
tients treated with PEG-IFNα+RBV as compared 
with treatment naïve elderly patients and to identify 
factors associated with HCC and end-stage liver dis-
ease (ESLD) development. Th e secondary aim was to 
evaluate PEG-IFNα+RBV treatment response and 
safety in elderly patients (≥60 years).
Patients and Methods
Study design and population
In order to analyze treatment response and safety 
profi le of PEG-IFNα and RBV combination therapy 
in elderly population, a retrospective cohort study that 
included 577 consecutive adult, treatment-naïve pa-
tients that started combination therapy between Janu-
ary 2003 and January 2013 was conducted at the Cro-
atian Reference Center for Viral Hepatitis, Zagreb, 
Croatia. Patients were stratifi ed by age into two groups: 
those aged ≥60 (n=92, 15.9%) and those aged <60 
years (n=485, 84.1%).
To determine the impact of PEG-IFNα+RBV 
treatment and achievement of SVR on the clinical 
outcomes of HCV infection in elderly population (≥60 
years), all consecutive CHC patients enrolled between 
2003 and 2013 were included in the study. In total, 142 
patients were included in the cohort that was followed 
for 3.56±1.87 years. Patients were stratifi ed in three 
categories: SVR group, non-SVR group and untreated 
patients. Selected endpoints were development of 
HCC, ESLD, and progression of liver disease, as mea-
sured by the aspartate aminotransferase-to-platelet 
ratio index (APRI) and fi brosis index based on four 
factors (FIB-4) scores.
Data collection and defi nitions
Records of all patients treated at the Department 
of Viral Hepatitis, University Hospital for Infectious 
Diseases, Zagreb (UHID) during the study period 
were extracted and used for collection of clinical and 
laboratory data. Patients were treated either with 
PEG-IFNα2a 180 μg/week (n=334, 57.9%) or PEG-
IFNα2b 1.5 μg/week (n=243, 42.1%) plus weight-ad-
justed RBV. Th e duration of therapy in HCV geno-
types 1 and 4 was 48 weeks, and in genotypes 2 and 3 
it was 24 weeks. Th erapy was discontinued in patients 
with genotype 1 and genotype 4 if the viral load de-
creased by less than 2 log HCV RNA copies/mL at 
week 12 compared with baseline values and if HCV 
RNA was still detectable at week 24.
Th e following demographic and laboratory data 
were analyzed: age, gender, baseline hemoglobin con-
centration, white blood cell count (WBC), absolute 
neutrophil count (ANC), platelet count, aspartate 
aminotransferase (AST), alanine aminotransferase 
(ALT), total serum protein and serum albumin, pre-
treatment HCV viremia, and genotype. HCV RNA 
quantifi cation was performed by COBAS Ampliprep/
COBAS TaqMan HCV test (Roche Diagnostics, Di-
agnostic Systems, Pleasanton, CA, USA). HCV geno-
typing was performed by VERSANT HCV Genotyp-
ing assay (LIPA, Bayer Diagnostics, Puteaux, Cedex, 
France). Liver biopsy was performed in a total of 427 
patients and the Ishak scoring system was used as an 
indicator of histologic activity15. Th e APRI and FIB-4 
scores were calculated for all patients and were used as 
a surrogate marker of disease severity16, 17. Th e primary 
outcome measured was SVR achievement defi ned as 
undetectable HCV RNA at 24 weeks after the end of 
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antiviral therapy. Secondary outcomes were rates of 
adverse events, rates of PEG-IFNα and/or RBV dose 
modifi cations and treatment discontinuation. In order 
to evaluate disease progression in elderly patients, data 
on the development of HCC, APRI, FIB-4 score and 
ESLD were retrieved from medical records of all pa-
tients that had ≥60 years at the time of diagnosing 
HCV at UHID between 2003 and 2013. Th e diagno-
sis of HCC was confi rmed on the basis of a verifi ed 
focal liver lesion by imaging techniques in accordance 
with the European Association for the Study of the 
Liver guidelines18. Th is study was conducted according 
to the ethical guidelines of the Declaration of Helsinki 
and was approved by the UHID Ethics Committee.
Statistical analysis
Demographic and clinical characteristics and labo-
ratory data were evaluated and presented descriptively. 
Th e χ2-test with Yates correction, Fisher exact test and 
Mann Whitney U test were used to compare the 
groups, as appropriate. All tests were two-tailed; a 
p<0.05 was considered statistically signifi cant. Binary 
logistic regression analysis was used to assess the inde-
pendent predictors of SVR. Cumulative incidence of 
HCC was estimated by the Kaplan-Meier method. 
Th e prognostic relevance of clinical variables and 
HCC occurrence was evaluated by univariate analysis 
with the log-rank test and by multivariate Cox regres-
sion analysis. Th e time frame for each outcome was 
defi ned as the time from diagnosing HCV infection 
until the onset of the event. Data were censored when 
individuals died from non-liver-related causes, re-
ceived a liver transplant, or were lost during follow-up. 
Th e strengths of association were expressed as odds 
ratio (OR) and the corresponding 95% confi dence in-
terval (95%CI). Statistical analyses were performed 
using Prism (ver. 5.0) statistical software (Graphpad 
Software, San Diego, CA, USA) and MedCalc for 
Windows®, ver. 11.5.1.0 (MedCalc Software, Mar-
iakerke, Belgium).
Results
Baseline characteristics of treated patients
A total of 346 men and 231 women aged 18-73 
years (44.18±12.6) were included in the study. Patients 
aged ≥60 comprised 15.9% of the study population. 
Th ere were six patients younger than 20, 249 (43.2%) 
patients aged 20-39, 118 (20.5%) patients aged 40-49, 
112 (19.4%) patients aged 50-59, 81 (14.0%) patients 
aged 60-69, and 11 (1.9%) patients aged >70. Patient 
baseline characteristics are shown in Table 1.
Elderly patients were more often infected with 
HCV genotype 1 (88.0%), had more severe histologic 
activity of the disease, as well as higher FIB4-score and 
lower platelet count and hemoglobin level. Important-
ly, elderly patients more frequently had comorbidities 
(65.2%), including hypertension (n=42, 45.7%), diabe-
tes (n=9, 9.8%), chronic obstructive pulmonary disease 
(n=10, 10.9%), hyperlipidemia (n=24, 26.1%), coro-
nary disease (n=13, 14.1%), and osteoporosis (n=7, 
7.6%). Although six (6.5%) patients had chronic renal 
impairment, none of our patients was treated with 
chronic dialysis.
Treatment safety, modifi cations 
and discontinuation
Th erapy had to be adapted in a substantial number 
of elderly patients. Reduction of PEG-IFNα and RBV 
was more frequently required and treatment was more 
frequently prematurely discontinued due to side eff ects 
in elderly patients. Data on treatment discontinuation 
and side eff ects are summarized in Table 2.
Neutropenia (≤1500 cells/μL), anemia and throm-
bocytopenia (≤50x109/L) more frequently developed 
in the elderly group. In addition, during the course of 
treatment, a decreased level of hemoglobin, ANC and 
platelets was more pronounced than in younger pa-
tients. Th e mean decrease in hemoglobin was 
39.73±25.71g/L in elderly versus 26.46±12.33g/L in 
younger patients (p=0.0265). Th e incidence of both 
anxiety and insomnia was higher in elderly patients. 
Th ere was no lethal outcome in either group during 
the treatment or in the 6-month follow-up period.
Treatment outcome
Th e analysis included data on all patients who re-
ceived at least one dose of medication (intention-to-
treat analysis). In the whole group, SVR was achieved 
in 339 (62.4%) patients; SVR rate was 53.8% for gen-
otype 1 and 80.1% for genotype 3.
In elderly patients, SVR rate was signifi cantly low-
er for genotype 1 (35.8% vs. 57.1%, p=0.0007), while 
there was no statistical signifi cance for genotype 3 
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Table 1. Baseline patient characteristics
≥60 years (n=92) <60 years (n=485) p valueb
Male sex 41 (44.57%) 305 (62.89%) 0.0016
Age (years) 63.8±3.7 40.4±10.1 <0.0001
Body weight (kg) 73.5±13.43 75.77±16.82 0.5151
Comorbidities 60 (65.22%) 96 (19.79%) <0.0001
Duration of infection (years)a 19.86±12.31 12.35±9.91 0.0009
Risk factors
Blood transfusion 42 (45.65%) 97 (20.00%)
0.0001
Intravenous drug use 12 (13.04%) 193 (39.79%)
Surgery/wounding 15 (16.30%) 43 (8.87%)
Sexual behavior 0 (0.00%) 20 (4.12%)
Other 1 (1.09%) 31 (6.39%)
Unknown 22 (23.91%) 101 (20.82%)
Liver biopsy (n=427)
Ishak score 
Ishak 0,1 4 (6.15%) 18 (4.97%)
0.0001
Ishak 2,3 19 (29.23%) 230 (63.54%)
Ishak 4,5 37 (56.92%) 108 (29.83%)
Ishak 6 5 (7.69%) 6 (1.66)%
Histology Activity Index (HAI)
HAI 1-8 24 (36.92%) 222 (61.33%)
0.0006HAI 9-12 26 (40.00%) 100 (27.62%)
HAI 13-18 15 (23.08%) 40 (11.05%)
Liver steatosis 39 (60.00%) 175 (48.34%) 0.1055
Moderate/severe steatosis 21 (32.31%) 78 (21.55%) 0.0779
Genotype
Genotype 1 81 (88.04%) 303 (62.47%)
<0.0001
Genotype 1a 8 (8.70%) 79 (16.29%)
Genotype 1b 59 (64.13%) 156 (32.16%)
Genotype 3 7 (7.61%) 156 (32.16%)
Other 4 (4.35%) 26 (5.36%)
HCV RNA, log10, IQR 5.85 (5.49-6.3) 5.84 (5.23-6.31) 0.3481
<600,000 IU/mL 36 (44.44%) 173 (46.51%)
0.8060
>600,000 IU/mL 45 (55.56%) 199 (53.49%)
Biochemical activity
AST (IU/mL) 40.9±27.21 69.78±71.13 0.0001
ALT (IU/mL) 51.31±49.65 108.2±125.1 <0.0001
Platelets (x109/L) 185.0±72.86 241.0±299.1 0.0038
Hemoglobin (g/L) 140.0±12.37 147.5±14.59 0.0107
APRI score 0.68±0.58 0.79±0.98 0.8552
FIB-4 score 2.39±1.43 1.24±1.03 <0.0001
aData available for 345 patients; bFisher exact test or Wilcoxon rank sum test, as appropriate; APRI = aspartate amino-
transferase-to-platelet ratio index; FIB-4 = fi brosis index based on four factors
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(57.1% vs. 82.0%, p=0.1271). Virologic response in 
young and elderly patients is summarized in Table 3.
However, since the majority of elderly patients had 
genotype 1 infection and signifi cant fi brosis (Ishak 
>3), subgroup analysis was performed and showed no 
statistical diff erences in genotype-1 SVR rates when 
adjusted for fi brosis score (Ishak ≤3: 66.7% (14/21) vs. 
69.8% (169/73), p=0.8016, and Ishak ≥4: 29.7% 
(11/36) vs. 43.6% (44/101, p=0.1714).
Factors associated with sustained viral response
In order to identify if age ≥60 is independently as-
sociated with lower SVR, we performed multiple lo-
gistic regression analysis taking confounders into ac-
count. All predictors were entered in a backward step-
wise logistic regression model with the SVR being the 
dependent variable (antiviral therapy (PEG-IFNα2a 
vs. PEG-IFNα2b), age (<60 years vs. ≥60 years), gen-
der, body weight (≤75 kg vs. >75 kg), HCV-genotype 
3 vs. non-3, extent of fi brosis (mild fi brosis: Ishak 0-3 
vs. signifi cant fi brosis: Ishak 4-6)). Statistically non-
signifi cant predictors were progressively excluded 
based on the likelihood ratio test. Multivariable model 
showed that age had no signifi cant infl uence on SVR. 
As expected, the best SVR predictor was genotype 3, 
while signifi cant fi brosis and RBV reduction were 
negatively associated with SVR, as shown in Table 4.
Similar results were obtained in subgroup analysis 
that focused on genotype 1, signifi cant fi brosis and 
RBV reduction. When only genotype 1 patients were 
included, fi brosis (OR 0.26, 95%CI 0.15-0.45, 
p<0.0001) and RBV reduction (OR 0.37, 95%CI 
0.18-0.77, p=0.0074) had a negative impact on SVR, 
while PEG-IFNα-2a treatment was positively associ-
ated with SVR (OR 1.99, 95%CI 1.15-3.43, p<0.0132). 
Next, we performed subgroup analysis on patients 
with signifi cant fi brosis (Ishak ≥4). Th e fi nal multivari-
able model included genotype 3 (OR 17.75, 95%CI 
2.06-152.28), PEG-IFNα reduction (OR 0.09, 95%CI 
0.01-0.75) and female sex (OR 2.62, 95%CI 1.26-
6.70), but again age was not found to be an indepen-
dent predictor of SVR.
Table 2. Treatment safety and tolerability
≥60 years <60 years p valuea




















12 (13.04%) 89 (18.35%)
0.2941
Dermatologic 11 (11.96%) 61 (12.58%) 1.0000
Respiratory 3 (3.26%) 27 (5.57%) 0.4520
Hypo/
hyperthyroidism




29 (31.52%) 203 (41.86%)
0.0649
Anxiety 42 (45.65%) 61 (12.58%) 0.0001
Depression 4 (4.35%) 19 (3.92%) 0.7743
Insomnia 48 (52.17%) 39 (8.04%) 0.0001
Headache 23 (25.00%) 103 (21.24%) 0.4120




18 (19.57%) 47 (9.69%) 0.0107
PEG-IFNα 
dose reduction
25 (27.17%) 38 (7.84%) 0.0001
PEG-IFNα 
and RBV dose 
reduction
14 (15.22%) 13 (2.68%) 0.0001
Th erapy 
discontinuation 
12 (13.04%) 20 (4.12%) 0.0019
aFisher exact test or Wilcoxon rank sum test; PEG-IFNα = pegylat-
ed interferon alfa; RBV = ribavirin
Table 3. Treatment response
≥60 years <60 years p value
Genotype 1
SVR 29 (35.80%) 173 (57.10%) 0.0007
Lost 
to follow-up
3 (3.70%) 13 (4.29%) 1.0000
Genotype 3
SVR 5 (71.43%) 128 (82.05%) 0.6136
Lost 
to follow-up
0 (0.00%) 13 (8.33%) 1.0000
Fisher exact test; SVR = sustained virologic response
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Incidence of heptatocellular carcinoma 
and disease progression in elderly patients
Of the 577 patients that received PEG-IFNα+RBV 
treatment in the study period, 256 (44.4%) patients 
were followed-up for more than 12 months after the 
end of treatment (98 SVR+ and 158 SVR- patients, 
with the mean follow-up of 4.57±2.71 years). Seven-
teen patients developed HCC at the mean age of 
56.21±11.66 years, corresponding to the incidence rate 
of 1.95 per 100 person-years. HCC was diagnosed in 
four patients that achieved SVR; in two patients with-
in 1 year after SVR, and in the other two at 3 and 4 
years, respectively, after achieving SVR. HCV RNA 
was tested at the diagnosis of HCC in all four of these 
patients, and they all were negative; two patients had 
Ishak fi brosis score 3, one patient had Ishak 4 and one 
Ishak 5; none had varices or decompensated liver dis-
ease at the time of HCC diagnosis. FIB-4 score >3.25 
(HR 4.57, 95%CI 1.65-12.61, p=0.0035) and age ≥60 
(HR 10.56, 95%CI 2.64-42.15, p=0.0009) were found 
to signifi cantly infl uence HCC incidence.
To further determine the impact of PEG-
IFNα+RBV treatment on the clinical outcomes of 
HCV infection in elderly population, we collected ad-
ditional data from untreated CHC patients that were 
aged ≥60 at the time of fi rst presentation at UHID 
between 2003 and 2013 and that were followed-up for 
at least 12 months. Overall, 142 patients were identi-
fi ed and included in the cohort (76 untreated and 66 
treated) that was followed-up for 3.56±1.87 years. 
During the follow-up, HCC developed in three pa-
tients with SVR, four patients from non-SVR group 
and nine untreated patients, corresponding to the inci-
dence of 3.6, 4.7 and 5.0 per 100 person-years, respec-
tively. Cox proportional hazard regression analysis 
identifi ed only baseline FIB-4 >3.25 (HR 12.1, 95%CI 
3.78-38.71, p<0.0001) to be independently associated 
with HCC development, while sex, PEG-IFNα+RBV 
treatment and SVR were not associated with HCC in 
elderly patients.
Table 4. Factors associated with sustained virologic response




Adjusted odds ratio 
(95%CI)
p value
Age ≥60 0.22 (0.11-0.44) <0.0001
FIB-4 >3.25 0.14 (0.02-0.93) 0.0418
Fibrosis (Ishak ≥4) 0.34 (0.22-0.54) <0.0001 0.34 (0.20-0.56) 0.0001
Genotype 3 6.89 (3.81-12.45) <0.0001 8.68 (3.83-19.64) <0.0001
PEG-IFNα-2a 1.50 (1.02-2.20) 0.0390
RBV reduction 0.34 (0.21-0.56) <0.0001 0.46 (0.24-0.90) 0.0238
PEG-IFNα reduction 0.37 (0.20-0.68) 0.0016
PEG-IFNα = pegylated interferon alfa; RBV = ribavirin; 95%CI = 95% confi dence interval
Fig. 1. Progression of liver disease in elderly patients 
as measured by APRI and FIB-4 score.
Frequencies of HCV infected elderly patients (combined SVR 
negative and treatment naïve) in diff erent APRI and FIB-4 stages 
at baseline, year 2 and year 4 of follow-up are shown. A signifi cant 
increase in stage 3 FIB-4 score was recorded between baseline and 
year 2 (p=0.006, χ2-test) and year 4 (p=0.003).
APRI: stage 1 <0.5, stage 2 ≥0.5<1.0, stage 3 ≥1.0;
FIB-4: stage 1 <1.45, stage 2 ≥1.45<3.25, stage 3≥3.25.
APRI = aspartate aminotransferase-to-platelet ratio index; FIB-4 = 
fi brosis index based on four factors
N. Papić et al. Chronic hepatitis C in elderly patients
Acta Clin Croat, Vol. 57, No. 1, 2018 67
Of 142 patients enrolled, 111 (78.1%) and 86 
(60.5%) patients had both year 2 and year 4 APRI and 
FIB-4 levels available, respectively. Th ere were no sig-
nifi cant diff erences in APRI and FIB-4 progression 
between non-SVR and untreated patients; during 4 
years, the proportion of patients with stage 3 APRI 
(>1.0) and FIB-4 (>3.25) increased from 34% and 24% 
at baseline to 41% and 38% at year 4, respectively (Fig. 
1). Any event of disease decompensation (ascites, en-
cephalopathy and/or variceal bleeding) developed in 
one patient from non-SVR group and in seven (9.21%) 
untreated patients.
Discussion
Th e combination of pegylated interferon and riba-
virin still remains the backbone or even standard ther-
apy in many resource-limited settings. Since the access 
to IFN free treatment is restricted, the way of priori-
tizing patients for treatment is of high importance. 
Interestingly, neither EASL nor AASLD in recently 
updated HCV treatment guidelines highlight elderly 
population for early treatment, refl ecting the defi cien-
cy of studies performed in this understudied group19,20.
While the safety and effi  cacy of PEG-IFNα+RBV 
therapy have been extensively reviewed, the perception 
of poorer outcomes and the potential diffi  culties asso-
ciated with adherence and drug interactions have re-
sulted in limited access for elderly patients. Results of 
our study show that older age is associated with sev-
eral negative predictors of treatment response, such as 
higher fi brosis score, FIB-4 score, genotype 1 infection 
and longer duration of infection. Th is is in clear con-
trast to other risk groups in Croatia, traditionally con-
sidered ‘diffi  cult-to-treat’, such as war veterans or in-
travenous drug users21,22. In addition, more comorbidi-
ties have been observed in elderly patients, mainly 
metabolic and cardiovascular diseases. According to 
multivariate analysis, signifi cant fi brosis, RBV reduc-
tion and genotype 1, but not the age, were associated 
with SVR. Response rates were high among elderly 
patients with genotype 1 infection and mild fi brosis 
(66%) and comparable with younger group. Similar re-
sults have been reported from France, Italy, Canada 
and the USA6,10,12,23. Meanwhile, reports from Japan 
consistently report lower SVR rates in elderly pa-
tients11,13. Although some of these studies had been 
performed before IL28B genotyping was recommend-
ed, this diff erence in response rates might be explained 
with diff erences in gene polymorphisms. Since the 
majority of patients from our cohort had been treated 
before IL28B genotyping was introduced, we did not 
include IL28B genotype in our analysis.
Huang et al. suggest that poor adherence is the ma-
jor reason for treatment inferiority in elderly patients 
and that SVR of 67% and 80% can be reached in gen-
otype 1 infected elderly patients, if their treatment 
lasts for ≥80% of its expected duration and if they 
achieve rapid virologic response (RVR), respectively24. 
In addition, analysis of our genotype 1 subgroup 
showed that fi brosis, RBV dose reduction and treat-
ment with PEG-IFNα-2a, but not the age, were inde-
pendent factors associated with treatment effi  cacy.
Th e results of our study also confi rmed that elderly 
patients had a higher incidence of dose reduction, 
mainly due to neutropenia, thrombocytopenia and 
anemia10,23,24. Th e most frequent age-specifi c side ef-
fects were anxiety and insomnia in up to 52% of el-
derly patients, but in contrast to other studies, severe 
depression occurred in a minority of elderly patients 
(4%)23-25. Importantly, treatment completion rate in 
our study was 86.9% in the elderly and 95.9% in the 
younger group. Th ese rates are signifi cantly higher 
than previously reported in similar ‘real-life’ studies 
that had treatment discontinuation rate of 21% to 
53%10,24. Overall, it seems that selected elderly patients 
can be treated with PEG-IFNα+RBV therapy, and 
achieve similar response rates as younger patients, with 
careful monitoring and management of more frequent 
side eff ects. Nevertheless, PEG-IFNα+RBV still re-
mains an option for genotype 1 infected patients with 
positive predictors of treatment response (RVR, F1-
F2 fi brosis and IL28 CC genotype) in many countries.
Th e long-term benefi ts of virologic cure are well 
known; SVR is associated with a more than 70% re-
duction in the risk of HCC and 90% reduction in the 
risk of liver-related mortality and liver transplanta-
tion26-28. However, the impact of age on HCV eradica-
tion and HCC development is still debatable. Th e 
mean age of HCC patients has been progressively in-
creasing over the last decades and in Europe it is cur-
rently reaching a peak at 70 years18. We examined the 
occurrence of HCC in our treated cohort that corre-
sponds to the incidence of 1.95 per 100 person-years. 
While FIB-4 score >3.25 and age ≥60 were signifi -
cantly associated with HCC development, SVR did 
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not signifi cantly reduce the incidence of HCC. Sev-
eral studies have previously reported that advanced age 
at HCV eradication is a risk factor for HCC develop-
ment in SVR patients5,26,27. Bruno et al. report that 
male sex and age >54 have a higher risk of developing 
HCC after SVR, suggesting that host-related factors 
and duration of the infection increase the risk of 
HCC29. Similarly, a study from Japan identifi ed age 
>55 at HCV eradication and heavy alcohol intake to 
be independently associated with the development of 
HCC within 5 years after HCV eradication, but long-
term risk of developing HCC remains for up to 15 
years30. Our study showed that in elderly population, 
the risk of HCC was higher in both treated and naïve 
patients as compared with younger patients, thus high-
lighting this population and the importance of early 
antiviral treatment in this group. Importantly, a pro-
portion of patients with FIB-4 >3.25 signifi cantly in-
creased in a 4-year period, increasing this risk even 
more. Recent reports argue the earlier initiation of 
treatment in patients with Metavir F0 and F1, which 
are recognized in current guidelines as a group in 
which treatment can be postponed; a long-term fol-
low-up study recorded signifi cantly better 15-year sur-
vival rates for SVR patients than for those whose 
treatment had failed or for those who remained un-
treated31.
Th e retrospective nature of this study may have 
represented a potential source of selection bias that 
might overestimate the incidence of HCC and SVR 
rates since our Center serves as the Referral Center for 
Viral Hepatitis in Croatia. Th e signifi cant number of 
lost-to-follow-up might represent information bias. 
However, the rates of SVR and HCC incidence in our 
study were consistent with those obtained in similar 
studies, as stated above.
In conclusion, the risk of disease progression and 
HCC development in elderly patients with CHC un-
derscores the need for early treatment of this ‘diffi  cult-
to-treat’ group. Although elderly patients often have 
worse prognostic factors and more frequent side eff ects 
to PEG-IFNα+RBV therapy, a subset of elderly pa-
tients can be safely treated with close monitoring, and 
may achieve comparable SVR rates as younger pa-
tients. Since older age is strongly associated with faster 
fi brosis progression, HCC and reduced quality of life, 
elderly patients should not be excluded from assess-
ment for treatment a priori. In the Croatian HCV 
treatment guidelines, elderly patients are now priori-
tized for antiviral therapy. Due to the persistent long-
term risk of HCC in elderly patients, even after 
achievement of SVR, surveillance should be continued 
over a prolonged period.
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Sažetak
LIJEČE NJE STARIJIH BOLESNIKA S KRONIČNIM HEPATITISOM C: 
RETROSPEKTIVNO KOHORTNO ISTRAŽIVANJE
N. Papić, J. Budimir, I. Kurelac, D. Dušek, D. Jugović, N. Krajcar i A. Vince
Učestalost kroničnog hepatitisa C (KHC) raste u starijim dobnim skupinama. Ciljevi ovoga istraživanja bili su utvrditi 
čimbenike povezane s razvojem hepatocelularnog karcinoma (HCC) i dekompenzirane jetrene bolesti te procijeniti učinko-
vitost i sigurnost terapije pegiliranim interferonom (PEG-IFNα) i ribavirinom (RBV) u starijih bolesnika. Retrospektivna 
kohortna studija je uključila sve bolesnike s KHC koji su liječeni PEG-IFNα + RBV između 2003. i 2013. godine u Klinici 
za infektivne bolesti “Dr. Fran Mihaljević”. Bolesnici u dobi od >65 godina češće su imali nepovoljne prognostičke čimbeni-
ke, tj. HCV-1 genotip, uznapredovali stadij fi broze i viši zbir indeksa fi broze zasnovan na četiri čimbenika (fi brosis index based 
on four factors, FIB-4). Trajni virusološki odgovor (sustained virologic response, SVR) je bio značajno niži (35,8% prema 57,1%), 
dok je učestalost smanjenja doze PEG-IFNα (27,2% prema 7,8%), RBV (19,6% prema 9,7%) i prekida liječenja (13,0% 
prema 4,1%) bila značajno češća u starijih bolesnika. Dob nije bila povezana sa SVR u multivarijatnoj analizi, a stariji bole-
snici su imali podjednaki SVR kao i mlađi bolesnici ovisno o stadiju fi broze (Ishak ≤3: 66,7% prema 69,8%). Tijekom pra-
ćenja HCC je dijagnosticiran u 18 bolesnika u dobi od >65 godina (3 SVR+, 4 SVR-, 9 neliječenih). Zaključno, stariji bole-
snici imaju podjednaku vjerojatnost postizanja SVR kao i mlađi, ali uz češće nuspojave. Budući da se komplikacije infekcije 
virusom hepatitisa C češće javljaju u ovoj populaciji, stariji bolesnici trebaju imati prednost u primjeni antivirusne terapije.
Ključne riječi: Hepatitis C, kronični – terapija; Terminalni stadij jetrene bolesti; Starija osoba; Hepatitis C – prognoza; Pegili-
rani interferon alfa; Imunoterapija; Antivirusni lijekovi
